GlassScriptPhysician profile
Mary E Dilorenzo
NPI 1437499506
$70,610.00
in general payments reported to CMS, 2019-2025
17 companies · $26K in 2025
The $26K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,222 · 2022: $3,323 · 2023: $25K · 2024: $15K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Travel and Lodging: $17K · Consulting Fee: $10K · Food and Beverage: $4,202 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,329.25 |
| Travel and Lodging | $17,141.93 |
| Consulting Fee | $10,302.50 |
| Food and Beverage | $4,201.68 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $20,238.90 | 2021-2025 | |
| Janssen Biotech, INC. | $13,168.82 | 2022-2025 | Imbruvica, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $10,268.76 | 2023-2025 | Calquence |
| Genmab U.S., INC. | $7,331.35 | 2023-2025 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $6,832.85 | 2023 | Imbruvica |
| Abbvie INC. | $6,469.26 | 2023-2025 | |
| Incyte Corporation | $4,392.15 | 2023-2024 | Jakafi, Monjuvi |
| Kite Pharma, INC. | $625.00 | 2021 | |
| Adaptive Biotechnologies Corporation | $374.00 | 2022-2023 | Clonoseq |
| Glaxosmithkline, LLC. | $226.65 | 2021-2022 | |
| Adc Therapeutics America, INC. | $142.71 | 2023 | |
| Beigene USA, INC. | $125.00 | 2021 | |
| Genzyme Corporation | $125.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $109.70 | 2024 | Reblozyl |
| Tg Therapeutics, INC. | $96.18 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $57.82 | 2023-2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $25.85 | 2025 | Ninlaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Dilorenzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.